Related Experiment Videos
Fosfomycin in acute bronchopneumopathies
Abstract:
Fosfomycin has been tested in 25 adult patients with bronchial or bronchopulmonary acute processes, of which 13 were simple acute processes of a greater or lesser severity, and 12 acutenesses of chronic bronchial processes. The germs found most frequently in the sputum cultures were Streptococcus pneumoniae and Klebsiella. Fosfomycin was used intramuscularly with doses of 4 g/day, for an average of 10 days. The results obtained were 16 cures, 7 improvements and 2 failures, which represents 92% success with 8% failures.
Insights
Fosfomycin effectively treated acute bronchial and bronchopulmonary infections in adults. This antibiotic achieved a 92% success rate, demonstrating its potential in managing common respiratory pathogens like Streptococcus pneumoniae and Klebsiella.
Area of Science:
- Infectious Diseases
- Pulmonology
- Pharmacology
Background:
- Acute bronchial and bronchopulmonary processes are common respiratory infections.
- Bacterial pathogens such as Streptococcus pneumoniae and Klebsiella frequently cause these infections.
- Effective antibiotic treatment is crucial for patient recovery and preventing complications.
Purpose of the Study:
- To evaluate the efficacy and safety of fosfomycin in treating adult patients with acute bronchial and bronchopulmonary infections.
- To determine the success rate of fosfomycin therapy in a clinical setting.
- To identify the spectrum of bacteria targeted by fosfomycin in respiratory infections.
Main Methods:
- A study was conducted on 25 adult patients diagnosed with acute bronchial or bronchopulmonary processes.
- Patients received intramuscular fosfomycin at a dosage of 4 g/day for an average of 10 days.
- Sputum cultures were analyzed to identify prevalent bacterial pathogens.
Main Results:
- Fosfomycin treatment resulted in a 92% success rate, with 16 patients cured and 7 showing improvement.
- Only 2 patients (8%) experienced treatment failure.
- Streptococcus pneumoniae and Klebsiella were the most frequently isolated bacteria from sputum cultures.
Conclusions:
- Intramuscular fosfomycin demonstrates high efficacy in treating adult patients with acute bronchial and bronchopulmonary infections.
- Fosfomycin is a viable therapeutic option against common respiratory pathogens like Streptococcus pneumoniae and Klebsiella.
- The observed success rate suggests fosfomycin's significant clinical utility in managing these respiratory conditions.